These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Interleukin 2 levels and urine cytology distinguish between cyclosporine toxicity and rejection in renal and liver allograft recipients. Cornaby A; Simpson M; Vann Rice R; Dempsey R; Madras P; Jenkins R; Monaco A Transplant Proc; 1988 Jun; 20(3 Suppl 3):827-30. PubMed ID: 3291322 [No Abstract] [Full Text] [Related]
26. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure. Waid T; Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546 [TBL] [Abstract][Full Text] [Related]
27. Treatment of chronic allograft rejection. Fan Y; Xie T; Xu D; Wang XH; Jin WH Chin Med J (Engl); 1993 Jul; 106(7):497-9. PubMed ID: 8243119 [TBL] [Abstract][Full Text] [Related]
28. The effect of cyclosporine on the early postoperative function of allografted kidneys with warm ischemic damage. Ohshima S; Fujita T; Asano H; Ono Y Transplant Proc; 1987 Feb; 19(1 Pt 3):2081-4. PubMed ID: 3547911 [No Abstract] [Full Text] [Related]
29. Cyclosporine as initial treatment for first acute rejection episodes in renal transplantation. Novick AC; Steinmuller D; Ho-Hsieh H; Streem SB; Cunningham R; Steinhilber D; Buszta C Transplant Proc; 1986 Jun; 18(3 Suppl 2):19-21. PubMed ID: 3520999 [No Abstract] [Full Text] [Related]
30. Clinical diagnosis and management of the renal transplant recipient with cyclosporine nephrotoxicity. Diethelm AG Transplant Proc; 1986 Apr; 18(2 Suppl 1):82-91. PubMed ID: 3515700 [TBL] [Abstract][Full Text] [Related]
31. Expression of class II antigens in human renal allografts: comparison of acute rejection, chronic rejection, and cyclosporine nephrotoxicity. Toma H; Tanabe K; Oba S; Horita S; Takahashi K; Teraoka S; Ota K Transplant Proc; 1987 Oct; 19(5):3719-20. PubMed ID: 3313898 [No Abstract] [Full Text] [Related]
35. The fate of living related donor kidney recipients after conversion from cyclosporine to azathioprine. Oka T; Omori Y; Aikawa I; Yasumura T; Nakai I; Matsui S Transplant Proc; 1987 Feb; 19(1 Pt 3):2012-6. PubMed ID: 3547905 [No Abstract] [Full Text] [Related]
36. Characteristics of recipients whose kidney allograft has functioned for more than 20 years. El-Agroudy AE; El-Dahshan KE; Abbass TM; Ismail AM; Shokeir AA; Ghoneim MA Exp Clin Transplant; 2008 Jun; 6(2):155-60. PubMed ID: 18816244 [TBL] [Abstract][Full Text] [Related]
37. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression. Kandaswamy R; Humar A; Casingal V; Gillingham KJ; Ibrahim H; Matas AJ Transplantation; 2007 Mar; 83(6):722-6. PubMed ID: 17414704 [TBL] [Abstract][Full Text] [Related]
39. Reversal of accelerated renal allograft rejection with FK 506. Woodle ES; Newell KA; Haas M; Bartosh S; Josephson MA; Millis JM; Bruce DS; Piper JB; Aronson AJ; Thistlethwaite JR Clin Transplant; 1997 Aug; 11(4):251-4. PubMed ID: 9267710 [TBL] [Abstract][Full Text] [Related]
40. Preliminary results of a randomized comparison of cyclosporine and Minnesota Antilymphoblast Globulin. Halloran PF; Lien J; Aprile M; White N Transplant Proc; 1982 Dec; 14(4):627-30. PubMed ID: 6301117 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]